Protocol | Published:

Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways

Nature Protocols volume 3, pages 891899 (2008) | Download Citation

Subjects

Abstract

We have applied noninvasive optical imaging technology to the in vivo hollow fiber assay, using tumor cell lines in which optical reporters are expressed in response to activation/inhibition of a specific molecular pathway. In vivo noninvasive imaging of molecular pathways in cells within hollow fibers enables a rapid and accurate evaluation of drug targets and provides useful insights to guide novel drug discovery. In this protocol we show, as an example, that a luciferase reporter, driven by the responsive element of nuclear factor NF-κB, was induced in cells within hollow fibers implanted in living mice, and a detailed procedure for in vivo bioluminescence imaging of hollow fibers is described. This approach can, in principle, be applied to image any molecular pathways of interest when appropriate reporter cells are generated. Hollow fiber encapsulation and implantation takes 2 d, and in vivo validation of reporter takes 1–2 weeks.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & The hallmarks of cancer. Cell 100, 57–70 (2000).

  2. 2.

    Molecular imaging and cancer. Mol. Cancer Ther. 2, 335–343 (2003).

  3. 3.

    , , & Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2, 41–52 (2000).

  4. 4.

    & Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol. Ther. 2, 196–202 (2003).

  5. 5.

    , & Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat. Med. 10, 1257–1260 (2004).

  6. 6.

    & NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749–759 (2005).

  7. 7.

    et al. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat. Med. 10, 643–648 (2004).

  8. 8.

    et al. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol. Imaging 2, 297–302 (2003).

  9. 9.

    & 50 Years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 11, 971–981 (2005).

  10. 10.

    , , , & Optical molecular imaging in drug discovery and clinical development. Expert Opin. Drug Discov. 2, 65–85 (2007).

  11. 11.

    et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57, 131–141 (1995).

  12. 12.

    et al. The hollow fiber assay: continued characterization with novel approaches. Anticancer Res. 20, 903–911 (2000).

  13. 13.

    et al. Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia 9, 652–661 (2007).

Download references

Author information

Affiliations

  1. Imaging Department, Merck Research Laboratory, Merck & Co., Inc., 770 Sumneytown Park, PO Box 4, West Point, Pennsylvania 19486, USA.

    • Guo-Jun Zhang
    • , Tsing-Bau Chen
    • , Richard Hargreaves
    • , Cyrille Sur
    •  & David L Williams Jr

Authors

  1. Search for Guo-Jun Zhang in:

  2. Search for Tsing-Bau Chen in:

  3. Search for Richard Hargreaves in:

  4. Search for Cyrille Sur in:

  5. Search for David L Williams in:

Corresponding author

Correspondence to Guo-Jun Zhang.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nprot.2008.52

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.